999 jili games download
Impartner Partner Relationship Management platform now available in the Microsoft Azure Marketplace
Join this golf club and you’ll get 7 ‘home’ courses across the US
Highway 11 lanes reopen after snowstorm blasted the region, stranding motoristsAmeraCell Accessible Affordable Bio Hacking in Katy Texas an American Life Sciences Clinic
St. John's squanders lead, falls to Baylor on double-overtime buzzer-beater in first loss of seasonHarry and Meghan’s polo docuseries to highlight ‘grit behind the glamour’
According to government sources, the last rites of Dr Manmohan Singh will be conducted with full state honours. It is also learned that all government programmes scheduled for tomorrow, December 27, will be cancelled. A national mourning of seven days is likely to be declared. The Narendra Modi-led cabinet is also expected to meet tomorrow at 11 AM. Dr Manmohan Singh, the former Prime Minister and veteran Congress leader, passed away on Thursday night at AIIMS Delhi due to age-related medical conditions. Dr Manmohan Singh Dies: Karnataka Announces 7-Day Mourning, Declares Holiday on December 27 As Former Prime Minister Passes Away at 92. All Government programs scheduled tomorrow are to be cancelled. National mourning of 7 days to be declared. Cabinet is to meet tomorrow at 11 am. Dr Manmohan Singh’s last rites to be conducted with full state honours: GoI sources pic.twitter.com/0yjEv1diDq — ANI (@ANI) December 26, 2024 (SocialLY brings you all the latest breaking news, viral trends and information from social media world, including Twitter (X), Instagram and Youtube. The above post is embeded directly from the user's social media account and LatestLY Staff may not have modified or edited the content body. The views and facts appearing in the social media post do not reflect the opinions of LatestLY, also LatestLY does not assume any responsibility or liability for the same.)"Discover the dynamic intersection of pharmaceuticals and medical devices, where innovative drug-device combinations are revolutionizing healthcare. BCC Research Study Projects 9.1% CAGR, with Market Growth from $129.4 Billion in 2024 to $199.8 Billion by 2029" BOSTON , Dec. 17, 2024 /PRNewswire/ -- According to the latest study from BCC Research, the demand for Global Markets for Drug-Device Combinations is expected to grow from $129.4 billion in 2024 to nearly $200 billion by the end of 2029, at a compound annual growth rate (CAGR) of 9.1% during the forecast period of 2024 to 2029. Drug-device combinations combine pharmaceutical drugs with medical devices to improve the effectiveness of treatments and convenience for patients. This report provides a thorough analysis of the market for drug-device combinations, analyzing trends from 2021, estimates for 2024, and projections from 2024 to 2029. It explores the future potential of these products, examines the competitive landscape, and covers regulatory aspects, market drivers, challenges, opportunities , and emerging technologies. The report also assesses the market shares of the leading companies. This report will prove to be valuable for all companies in the market, including recent entrants, government agencies, and other organizations interested in drug-device combinations. It offers insights into the markets of various regions, making it useful for companies looking to expand their geographic reach. Interesting Facts about Drug-Device Combinations Smart Biomaterials : Smart biomaterials are transforming precision medicine by responding to the body's signals to release drugs exactly when needed. Advances in nanotechnology and gene therapy are making personalized drug delivery more effective, improving patient outcomes and reducing side effects. This technology shows promise for treating conditions like Alzheimer's and certain cancers. Innovative Drug Delivery Solutions : The company ArQ-Bios is tackling the challenges of delivering high-dose, high-viscosity, and high-volume medications. Its innovative device designs allow patients to administer treatments at home easily and accurately, reducing the risk of errors. This is especially important as the demand for home-based care and self-administered biotherapeutics continues to grow. To gain more insights into Global Markets for Drug-Device Combinations, click here Factors contributing to the growth of this market include: Wide range of potential applications : Combination products, which integrate drugs and medical devices, have a wide range of potential applications. These products can be used in many medical fields They can be used for targeted drug delivery in cancer treatment, to provide controlled release of medications for chronic conditions, or combine diagnostic tools with therapies for more personalized healthcare. Growing prevalence of chronic diseases . : More people are being diagnosed with chronic diseases such as diabetes, heart disease , and cancer. This growing prevalence is due to factors such as aging populations, unhealthy lifestyles, and better diagnostic tools. As these long-term illnesses become more common, there is a greater need for effective treatments and healthcare solutions to manage them. Integrating homecare trends with drug delivery advance: Patients are gaining more control over their own healthcare due to trends in homecare and advanced drug delivery technologies. These advances allow patients to administer their treatments at home, making healthcare more convenient and accessible. This integration means patients can manage their conditions more effectively without frequent visits to healthcare facilities. Request a Sample Copy of Global Markets for Drug-Device Combinations Report Synopsis Market Segmentation The global market for drug-device combinations can be segmented by: 1. Product Type Drug/biologic-device combination products Drug/biologic-device combination products include a range of items such as drug-eluting stents (DES) for keeping arteries open, prefilled syringes (PFS) for easy injections, inhalers and nebulizers for respiratory treatment, wound care products for faster healing, implants for various medical needs, antimicrobial catheters to prevent infections, transdermal patches for continuous drug delivery through the skin, and photodynamic therapy for targeted treatments. These products combine medications with medical devices to enhance treatment effectiveness and patient convenience. Drug-biologic combination products Drug-biologic combination products include antibody-drug conjugates (ADCs), which link antibodies to drugs for targeted cancer treatment, and monoclonal antibodies (mAbs), which are designed to specifically target and neutralize harmful pathogens or cancer cells. These products combine the benefits of biologics with drugs to enhance treatment precision and effectiveness. 2. Application: Applications for drug-device combinations include areas such as cardiovascular diseases, metabolic disorders, respiratory conditions, and wound care products. It also includes oncology for cancer treatment, orthopaedic diseases for bone and joint issues, and other specialized areas. This report on drug-device combinations addresses the following questions: Innovative Startups CraniUS : Based in Baltimore, Md. , CraniUS is a neuroscience-focused startup developing a groundbreaking device that delivers medicine directly to the brain. This innovative implant bypasses the blood-brain barrier using a novel wireless charging system, making it highly effective for treating chronic brain diseases. In October 2022 , CraniUS raised $19.4 million in a Series A funding round from private investors. Emergent BioSolutions : Emergent BioSolutions' announced that Narcan Naloxone HCl Nasal Spray 4 mg became available over-the-counter nationwide and online starting in September 2023 . Easy accessibility to this type of product is crucial for responding to opioid emergencies, especially given the high rate of overdoses from synthetic opioids like fentanyl. Narcan Nasal Spray can help reverse opioid effects while emergency services are on the way. Leading companies in the market include: SMITH+NEPHEW TERUMO CORP. STRYKER MEDTRONIC JOHNSON & JOHNSON SERVICES INC. BOSTON SCIENTIFIC CORP. Becton Dickinson B. BRAUN SE ABBOTT 3M Related reports include: Conventional and Alternative Pain Treatment Markets : This report includes a detailed competitive analysis, market drivers, restraints, opportunities, and emerging technologies. The market is segmented by pain management type into pharmaceuticals and devices and by application into pain types such as orthopedic, surgical, and cancer pain. The market is divided into the regions of North America , Europe , Asia-Pacific , Latin America , and the Middle East and Africa , with specific country data provided. Market projections extend to 2029. Chronic Disease Management: Therapeutics, Device Technologies, and Global Markets : This report segments the market by product type (pharmaceuticals, biologics, medical devices, and digital therapeutics), application (disease categories such as cancer and cardiovascular conditions), end user (hospitals, home care), and geographic region ( North America , Europe , Asia-Pacific , and RoW). The report also examines market drivers, restraints, opportunities, and the competitive landscape, including the market shares of leading companies. Directly purchase a copy of the report from BCC Research. For further information or to purchase, please contact [email protected] . About BCC Research BCC Research reports provide objective, unbiased measurement and assessment of market opportunities. Our industry analysts' goal is to help you readers make informed business decisions, free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: [email protected] , Phone: +1 781-489-7301 For media inquiries, email [email protected] or visit our media page for access to our market research library. Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg SOURCE BCC Research LLC
The PGA Tour is making the most sweeping changes to its eligibility in more than 40 years by eliminating 25 tour cards, along with shrinking the size of its fields. The all-exempt tour had been in place since 1983, meaning the top 125 players from the official money list — now the FedEx Cup standings — kept a full PGA Tour card the following season. That changes in 2026 after the PGA Tour policy board approved a new priority list on Monday. Only the top 100 players will earn full tour cards for the following year. The top 30 from the developmental Korn Ferry Tour used to advance to the PGA Tour. That number now goes to 20. Five players from qualifying school will get cards — it previously was the top five and ties. The tour also is doing away with 156-man fields except for two tournaments held on multiple courses. Most tournaments will have 120 players before Daylight Saving Time, then 132 players in spring and a maximum of 144 players in the summer months. Here's a look at what's behind the changes and what it means: The all-exempt tour led to a bloated membership in which nearly 200 players were on the membership rolls through one exemption or another, and those toward the bottom of the priority list could not get into all the tournaments they wanted to play. Those who graduated from the Korn Ferry Tour, for example, could only get in three or four tournaments over the first few months of the season, giving them a disadvantage. The PGA Tour believes that limited full status to the top 100 instead of the top 125 will give everyone who earns a card a fair chance at getting into regular tournaments. Priority to get into tournaments starts with winners of the majors and The Players Championship over the last five years; winners of the Arnold Palmer Invitational, Memorial and Genesis Invitational the last three years; tournament winners the last two years and career money leaders. Next are the top 125; players who have been given a medical extension; and then the 45 players who earned cards from the Korn Ferry Tour, European tour and Q-school. After that are those who finished from No. 126 to No. 150 in the FedEx Cup. All of them have PGA Tour cards. But there's not room for them in every tournament. The most common refrain in golf is to play better to get better status. Those who perennially finish in the top 100 should have no trouble keeping their cards, and they will have fewer players to beat because the fields will be smaller. It also helps newcomers from the Korn Ferry Tour, European tour and Q-school. They can expect to get into every regular tournament, increasing their odds of getting into some of the $20 million signature events. The PGA Tour, already the strongest circuit in golf, is likely to be even more competitive with a greater chance of the top names in contention. The tour also hopes — this is still to be determined — it will improve the pace of play and keep rounds from spilling over into the next day. Players like Peter Malnati and Taylor Pendrith come to mind. Under the new system, neither would have had a full PGA Tour card this year and likely would not have been in the fields for the tournaments they won — Malnati at the Valspar Championship and Pendrith at the CJ Cup Byron Nelson. Those wins make them exempt through 2026. Players who have not performed consistently well, who seem to struggle each year just to finish in the top 125, will have to be at their best to stay on tour. The PGA Tour also is reducing the four spots from Monday qualifiers at open tournaments. Now there will only two spots for the 132-man fields and none for fields of 120 players. One of golf's charms is how one week can change a career. Then again, there has been only one Monday qualifier to win in the last five years — Corey Conners in the 2019 Texas Open. The new eligibility starts in 2026, so that puts a huge emphasis on playing well this year knowing that only the top 100 will keep full status. The four majors are not run by the PGA Tour. The Masters has the smallest field, typically fewer than 100 players. The U.S. Open, British Open and PGA Championship have 156-man fields. The Players Championship, the premier event run by the PGA Tour, is reducing its field from 144 players to 120. AP golf: https://apnews.com/hub/golfZERO Self-Awareness: Andrew Cuomo's Tone Deaf Thanksgiving Wish Gets ROASTED Like a Holiday Turkey
NuScale Power (NYSE:SMR) Trading Up 6.5% – Here’s What Happened